XP-8121

About Xeris Biopharma

Xeris Biopharma is a commercial-stage company focused on transforming drug delivery through its proprietary formulation platforms, XeriSol™ and XeriJect™, which enable stable, ready-to-use injectables. Its strategy is anchored by the commercial success of Gvoke® (glucagon) for severe hypoglycemia and a pipeline targeting neurology and cardiology. The company aims to improve patient care by eliminating reconstitution, enabling home administration, and reducing healthcare system burdens through its innovative delivery solutions.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals' mission is to develop and commercialize novel, ready-to-use injectable drug formulations that overcome stability and delivery challenges. The company has successfully leveraged its proprietary technology platforms to bring multiple products to market, including Gvoke® for severe hypoglycemia and Keveyis® for primary periodic paralysis. Its strategy focuses on expanding its commercial portfolio, advancing a deep pipeline of 19+ candidates, and forming strategic partnerships to apply its formulation expertise to a broad range of therapeutics. Xeris operates as an integrated biopharma company, controlling development, manufacturing, and commercialization.

Therapeutic Areas